For millennia, humans have relied on the ability of plants to produce useful medicines. Recent advances in genetic engineering help us control the natural abilities of plants and transform them into biological factories. The practice is also called ‘pharming’.
Plants have been an alternative production platform for biologics for many years. At Helico, we focus on the development of plant production models for biologics and biosimilars. Using plants to produce therapeutic molecules has many advantages, thanks to their cellular complexity:
• Cost-effective development and production timelines
• Improved manufacturing capabilities
• Low capital expenditure
• Localised production using small green houses
Synthetic biology is a challenging field that requires insight and intuition to produce plausible designs for life-changing drugs or medicine production systems. The development of advanced bioinformatics tools, over the past decade, has accelerated structural biology research and drug discovery programs around the world.
Helico creates opportunities to realize the potential of ‘pharming.’ Specifically, we can help you with:
Modeling of Biochemical interactions in plants.
Validation of the molecule of interest expressed in plants.
Generation of stable lines. Production of seed available for licensing.
At Helico, we develop plant models for pharmaceutical and biotech clients. We provide expertise and services in the following areas:
Development of plant production models to produce a targeted biologic or biosimilar.
Development and validation of machine learning algorithms to accelerate biological production of plant-based biologics that deliver high drug expression.
We work to generate better plant models, custom-made for the protein of interest to allow increased yields.
We design stable lines: plant lines are created, tested and validated in our laboratories before being licensed. Our vision is to produce seeds that can be grown anywhere, making the model highly scalable.
Ilya Vensky, CEO